Nalaganje...

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

The aims of this phase III study were to assess the efficacy and safety of telaprevir in combination with peginterferon alfa-2b (PEG-IFN) and ribavirin (RBV) for difficult-to-treat patients who had not achieved sustained virological response (SVR) to prior regimens in Japan. The subjects were 109 re...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Hayashi, N, Okanoue, T, Tsubouchi, H, Toyota, J, Chayama, K, Kumada, H
Format: Artigo
Jezik:Inglês
Izdano: Blackwell Publishing Ltd 2012
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3489056/
https://ncbi.nlm.nih.gov/pubmed/22239511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2893.2011.01528.x
Oznake: Označite
Brez oznak, prvi označite!